28bio

The issue is not discovery.
It’s prediction.

Measure human neural activity linked to clinical safety and efficacy to better predict patient response to drugs.

The Endurance Study

CNS-3D Brain Organoids Predict Clinical Seizure Liability

The Endurance Study is a retrospective, non-interventional study evaluating the predictive performance of CNS-3D Brain Organoids in small molecules with documented human clinical outcomes from 120,551 patients and known positive controls.

The study focuses on seizure liability, one of the most challenging and regulatory-critical CNS adverse effects to predict in neurological drug development.

Study Overview

Top-Line Results

83% sensitivity and 89% specificity

predicting clinical seizure liability

13x more predictive

than animal models

The Endurance Study results outperform previously published data on 2D and 3D cell-based assays and animal models and are in line with guideline-recommendations from regulatory agencies.

28bio

The issue is not discovery.It’s prediction.

CNS-3D Brain Organoids Predict Clinical Seizure Liability

83% sensitivity and 89% specificity

13x more predictive

The issue is not discovery.
It’s prediction.